^
    Back
    Association details:
    Biomarker:FLT3 D698N
    Cancer:Acute Myelogenous Leukemia
    Drug:Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    ASH 2019
    Title:

    FF-10101 Retains Potent Inhibitory Activities Against Resistant Mutations to FLT3 Inhibitors, Newly Identified in Random Mutagenesis Screens

    Published date:
    11/06/2019
    Excerpt:
    FF-10101 (GI50, 0.73 nM), quizartinib (GI50, 0.99 nM) and crenolanib (GI50, 19 nM) retained potency against FLT3-ITD+D698N, while midostaurin (GI50, 47 nM) did not have a potency.
    DOI:
    https://doi.org/10.1182/blood-2019-124632